Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )
20 Jun 2019

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
20 Jun 2019

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma

Michael Fuchs - University Hospital of Cologne, Cologne, Germany
PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma ( Michael Fuchs - University Hospital of Cologne, Cologne, Germany )
20 Jun 2019

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
20 Jun 2019

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )
20 Jun 2019

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA
Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )
18 Jun 2019

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )
18 Jun 2019

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India
Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )
18 Jun 2019

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA
Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )
18 Jun 2019

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma

Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold
Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma ( Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold )
15 Jun 2019